Navigating the New 20% Discount Rule for Combination Drugs: What You Need to Know
The healthcare sector in Germany continues to evolve as the government introduces new measures aimed at controlling costs while maintaining access to
German Market Access – Simplified
Everything you need to know in one place, explained in simple terms
The healthcare sector in Germany continues to evolve as the government introduces new measures aimed at controlling costs while maintaining access to
In April 2024, I wrote a guest post for Market Access Today. Introduction Entering the dynamic realm of pharmaceutical pricing in Germany,
Are confidential drug prices coming to Germany? Until now, the reimbursed prices of drugs are in the public domain (Lauer Taxe), but
Introduction Entering the dynamic realm of pharmaceutical pricing in Germany, we find ourselves immersed in a landscape defined by regulations, negotiations, price
On 25 August 2022, Janssen has announced that they have withdrawn the lung cancer drug Rybrevant (amivantamab) from the German market with
In March 2022, Lauterbach shared a non-authorized draft of his reform plans to stabilise the SHI funds finances. However, this draft version
The Lauer Taxe is a database of all pharmaceutical entities, e.g. drugs, medical devices and also remedies, and their prices.
In this post, I am discussing the different types of prices, price discounts and rebates, and who is paying what.
Currently, in Germany, free pricing applies in the first year. This means, at the time of launch in the German market, pharmaceutical companies are free to set the price for their product with a new chemical entity (NCE). This price is then valid for the first 12 months from the day of launch.
On 6 December 2021, Prof. Dr. Karl Lauterbach was announced as the new German health minister. This might mean quite a lot